Navidea Biopharmaceuticals Inc (NAVB) Short Interest Update

Share on StockTwits

Navidea Biopharmaceuticals Inc (NYSEAMERICAN:NAVB) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,860,498 shares, an increase of 16.0% from the January 15th total of 7,639,128 shares. Approximately 5.8% of the company’s stock are short sold. Based on an average daily volume of 503,692 shares, the days-to-cover ratio is presently 17.6 days.

Navidea Biopharmaceuticals stock traded up $0.01 during midday trading on Monday, hitting $0.16. 467,600 shares of the stock were exchanged, compared to its average volume of 446,464. Navidea Biopharmaceuticals has a 52-week low of $0.10 and a 52-week high of $0.42.

ILLEGAL ACTIVITY WARNING: This article was originally reported by Zolmax and is the sole property of of Zolmax. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://zolmax.com/investing/navidea-biopharmaceuticals-inc-navb-short-interest-update/2892418.html.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The company operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages; and NAV4694, a fluorine-18 labeled positron emission tomography imaging agent for use as an aid in the imaging and evaluation of patients with signs or symptoms of Alzheimers disease and mild cognitive impairment.

Further Reading: Return on Equity (ROE)

Receive News & Ratings for Navidea Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Navidea Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

HCA Healthcare  Bond Prices Fall 1.5%
HCA Healthcare Bond Prices Fall 1.5%
Navidea Biopharmaceuticals Inc  Short Interest Update
Navidea Biopharmaceuticals Inc Short Interest Update
Analysts’ Recent Ratings Changes for Gaming and Leisure Properties
Analysts’ Recent Ratings Changes for Gaming and Leisure Properties
Castle Brands Inc  Sees Significant Growth in Short Interest
Castle Brands Inc Sees Significant Growth in Short Interest
Bank of Commerce Holdings  Given $12.50 Average Target Price by Brokerages
Bank of Commerce Holdings Given $12.50 Average Target Price by Brokerages
Carbonite  Cut to “Hold” at Zacks Investment Research
Carbonite Cut to “Hold” at Zacks Investment Research


Leave a Reply

 
© 2006-2019 Zolmax.